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Abstract Current models of receptor activation are based on
either of two basic mechanisms: agonist induction or conforma-
tional selection. The importance of one pathway relative to the
other is controversial. In this article, the impossibility of distin-
guishing between the two mechanisms under a thermodynamic
approach is shown. The e¡ect of receptor mutation on the con-
stants governing ligand^receptor equilibria is discussed. The
two-state model of agonism both in its original formulation
(one cycle) and including multiple active states (multiple cycles)
is used. Pharmacological equations for the double (two cycles)
two-state model are derived. The simulations performed suggest
that the double two-state model of agonism can be a useful
model for assessing quantitatively the changes in pharmacolog-
ical activity following receptor mutation.
$ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Agonist induction and conformational selection are two
pharmacological mechanisms widely used in receptor theory.
Agonist induction involves the generation of an active (R*)
receptor state as a consequence of agonist binding to the in-
active (R) state whereas conformational selection implies the
selective binding of the agonist to di¡erent receptor confor-
mations present in the system [1]. Although the importance of
one mechanism relative to the other has been debated before
[2,3], some recent studies claiming the primacy of agonist in-
duction over conformational selection [4^6] indicate that the
question remains open. As an example, Hunyady et al. stated
[4], from experiments with N111G mutant AT1 angiotensin
receptor, that conformational selection is not su⁄cient to ex-
plain the mechanism of receptor activation and that agonist
induction should be considered as a general mechanism of G
protein-coupled receptor activation. This assumption agrees
with a previous proposal [5] remarking that agonist^receptor
interaction for AT1 angiotensin receptor is not passive (con-
formational selection) but rather that the agonist coordinates
the transition of R to R* (agonist induction) through the
formation of agonist-induced pre-active states. In line with
these ideas, the sequential binding model [6] for the activation
of the L2 adrenergic receptor suggested that binding of agonist
does not occur directly to R* but sequentially, resulting in a
series of conformational states that are intermediates between
R and R*. However, it may not be possible to distinguish
between the two mechanisms in the case of constitutively ac-
tive receptors, under a thermodynamic approach. To illustrate
this assessment, the two-state model of receptor activation
both with a single [7] and with multiple [8] active states will
be used because of the simplicity of the resulting equations. It
will be assumed hereinafter that R* is the conformation able
to activate G proteins.
2. Receptor selection and agonist induction within the two-state
model of agonism
Scheme 1 displays the equilibrium cycle for a wild-type
receptor under the two-state model with a single active state
[7].
R and R* are the inactive and active free receptor, respec-
tively, and AR and AR*, the corresponding ligand-bound
species. The equilibrium constants are de¢ned as:
X ¼ ½R

½R ; Z ¼
½A½R
½AR ; T ¼
½A½R
½AR ; Y ¼
½AR
½AR ð1Þ
Because only three from the {X, Z, T, Y} set of constants
are independent, the de¢nition of either of them can be related
to the others [9]. For instance, Y can be expressed as Y=XZ/
T. The degree of agonist induction (Y) depends on the extent
of basal response (X) and on the selectivity (Z/T) of the ago-
nist for the receptor states.
The functional response of a receptor is related to the con-
centration of receptors in the active form ([R*]+[AR*]) which,
expressed as a fraction (fR*) of the total receptor concentra-
tion ([Rt] = [R]+[R*]+[AR]+[AR*]) gives [7] :
f R ¼ T þ ½ATaþ b½A; where a ¼ 1þ
1
X
and b ¼ 1þ T
XZ
ð2Þ
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; where a ¼ 1þ 1
X
and b ¼ 1þ 1
Y
ð3Þ












using the agonist induction concept. Eqs. 2 and 3 are algebrai-
cally equivalent. A mechanistic distinction between them
would be possible if we could separate the molecular from
the molar scenario. At a given time, a particular AR* molec-
ular complex is formed either via conformational selection
(from R*) or via agonist induction (from AR). However,
the route followed by each individual molecule is hidden to
an external observer who will perceive only the molar rela-
tionships de¢ned by the aforementioned equilibrium constants
(see [10] for a discussion between molecular and molar mod-
els).
3. Mutant receptors and equilibrium constants for receptor
activation
Experiments with mutant receptors can shed new light on
signal transduction processes. In fact, the necessity for an
explicit equilibrium between inactive and active receptor states
was proposed [11] on the basis of ¢ndings from mutation
experiments. However, a word of caution is needed when
translating the properties of a mutant receptor to its parent
wild-type. It is likely that mutation of a residue will change
the molecular features of the receptor states. Accordingly, an
e¡ect on some or all the equilibrium constants is expected.
Scheme 2 displays the equilibrium cycle for a mutant recep-
tor under the two-state model.
In analogy to the case of the wild-type receptor, the rela-
tionship Y4 =X4Z4/T4 is obtained. I have assumed that, in
theory, any constant involved in these equilibria may change
after mutation. This assumption is not new, inasmuch as the
hypothesis that the active conformation of a mutant receptor
may not be the same as the one of the wild-type has been
considered previously [9].
The response pro¢le of a mutant receptor expressed as f R4 ,
using either the conformational selection (Eq. 2) or the ago-
nist induction (Eq. 3) approaches, will di¡er from the wild-
type if any of the equilibrium constants changes. Thus, a li-
gand can be a full agonist in the mutant receptor and partial
in the wild-type and vice versa. The exclusion of conforma-
tional selection and the proposal of agonist-induced pre-active
states was suggested [5] from the di¡erent behavior of
[Sar1,Ile4,Ile8]Ang II, an analogue of hormone Ang II, in
wild-type and N111G AT1 receptors. [Sar1,Ile4,Ile8]Ang II
fully activated the mutant receptor, but, although it bound
to the wild-type it did not activate it. This ¢nding cannot be
explained by Scheme 1 if the receptor active state, R*, is
required to be the same for the wild-type and the mutant
receptors. Consequently, an agonist-induced pre-active state
ARP, which coincides with the conformation of the mutant
receptor, was suggested [4,5] and receptor selection (direct
binding of A to R*) was ruled out. Scheme 3 re£ects a pos-
sible model corresponding to the authors’ hypothesis. This
scheme also contains the sequential binding model [6] men-
tioned above.
The model expressed by Scheme 3 is, in thermodynamics
terms, incomplete: a chemical equilibrium between {A, R*}
and AR* with its corresponding equilibrium constant is miss-
ing. Scheme 2, which includes a new active state for the mu-
tant receptor, overcomes this apparent con£ict without the
necessity of postulating agonist-induced pre-active receptor
states. Scheme 2 can explain some published [4] pharmacolog-
ical results : (i) Ang IV is more potent in the mutant receptor
than in the wild-type (WT): if T46T then Amutant50 6A
WT
50 ; (ii)
[Sar1,Ile4,Ile8]Ang II is an antagonist in the wild-type recep-
tor: if T=Z then fmaxR =basal response; (iii) [Sar
1,Ile4,Ile8]Ang
II is an agonist in the mutant receptor: if T46Z4 then
fmaxR s basal response.
Scheme 1. The single two-state model for a wild-type receptor.
Scheme 2. The single two-state model for a mutant receptor.
Scheme 3. Agonist induction mechanism with pre-active species.
Scheme 4. The double two-state model.
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4. The double two-state model of agonism
The two-state model of agonism is the simplest model able
to explain receptor constitutive activity or inverse agonism
pharmacological properties. In the present paper this model
allows us to show the functional equivalence between confor-
mational selection and agonist induction mechanisms with
algebraic simplicity. However, the two-state model appears
to be insu⁄cient in some complex pharmacological situations,
for instance, those situations requiring the inclusion of multi-
ple active receptor states (see [12^15] for a review). It can be
seen, however, that this property is, in part, implicit in
Scheme 2. Comparison of Schemes 1 and 2 shows that phys-
iological response arises from two states of the receptor: R*
(wild-type) and R*4 (mutant). In other words, G proteins are
£exible enough to recognize several active receptor states. Let
us address the simplest case of multiple receptor states in
which two inactive (R1, R2) and two active (R1*, R2*) states
are already present in the wild-type receptor. Within the
framework of the two-state model, two cycles can be con-
structed to form the double two-state model (Scheme 4).






½ARi ; Ti ¼
½A½Ri 
½ARi 




with i ¼ 1 or 2 ð4Þ
The equilibrium constants connecting both cycles are de-
¢ned as:










Scheme 4, which is an extension of the classical two-state
model (Scheme 1), is the simplest case of the multi-two-state
model presented earlier [8]. It is worth noting that the multi-
two-state model is essentially equivalent to the multistate
probabilistic model of receptor activation [16,17], in which it
is assumed that the receptor can explore a very large number
of conformations and that function arises as a macroscopic
result of the distribution of these microscopic states. Here, the
equation for the agonist concentration^e¡ect relationship and
the corresponding geometric parameters are derived for the
particular case of two cycles (Scheme 4). Pharmacological
activity now comes from two receptor sources: R1*+AR1*
(Cycle 1) and R2*+AR2* (Cycle 2). Cycles 1 and 2 are not
independent. The relation between them is modulated by four
(a12, b12, c12, d12) equilibrium constants. If we use the receptor
selection mechanism, the fraction of active receptors
f R ¼
½R1 þ ½AR1 þ ½R2 þ ½AR2
½R1 þ ½R1 þ ½AR1 þ ½AR1 þ ½R2 þ ½R2 þ ½AR2 þ ½AR2
may be written as:
f R ¼ T þ ½ATaþ b½A; where T ¼ T1T2W
X 1 þ X 2a12
X 1T2 þ X 2T1a12;
a ¼ 1þ 1þ a12
X 1 þ X 2a12;
and b ¼ 1þ T
ðX 1 þ X 2a12ÞW Z1Z2Z2 þ Z1a12
ð6Þ










Eq. 6 contains the general pharmacological expressions for
the double two-state model. The contribution of one cycle
relative to the other is determined by the link constant a12
(this is an arbitrary election, we could have chosen b12 or
c12 or d12 instead) whose value may change after mutation.
The agonist response of a particular ligand depends on its
selectivity towards inactive and active receptor conformations
within each cycle and on the ratio of one cycle relative to the
other (a12). Thus, a12 translates in molar terms the molecular
rearrangement caused by receptor mutation. Two limit cases
may be considered: a wild-type receptor in which Cycle 1 is
majority (a12I1) and a mutant receptor in which Cycle 2 is
majority (a12E1). These limit cases correspond to Schemes 1
and 2 for wild-type and mutant receptors under the single
two-state model of agonism. Between these limit situations a
continuum of system states are possible according to the a12
value. To illustrate the potential utility of the double two-state
model of agonism, let us address some typical pharmacolog-
ical issues related to mutant receptors.
Fig. 1. Simulation of concentration^e¡ect curves resulting from the
double two-state model (Scheme 4; Eq. 6). For simplicity, the frac-
tion of receptors in the active state (fR*) is considered to represent
the observed e¡ect. The values for the parameters included in Eq. 6
are the following: X1 =X2 = 1036 ; Ligand 1: T1 = 1039, Z1 = 1,
T2 = 1, Z2 = 1; Ligand 2: T1 = 1, Z1 = 1, T2 = 1039, Z2 = 1. Panel A
represents a wild-type receptor in which Cycle 1 is majority
(a12 = 1036) ; panel B represents a mutant receptor in which Cycle 2
is majority (a12 = 106); and panel C represents a system in which
both cycles are balanced (a12 = 1).
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4.1. The agonist^antagonist identity of a ligand depends on the
system
Fig. 1 shows the concentration^e¡ect curves for two ligands
under the double two-state model of agonism (Eq. 6). Panel A
corresponds to a particular wild-type receptor (a12 = 1036 ;
Cycle 1 is majority) whereas panel B represents a particular
mutant receptor (a12 = 106 ; Cycle 2 is majority). In addition,
panel C characterizes a system in which the two cycles are
equally weighted (a12 = 1). The values for the rest of parame-
ters included in Eq. 6 are shown in the ¢gure legend. The
equilibrium between R and R* receptors is assumed to be
the same in both cycles (X1 =X2). Ligand 1 is de¢ned as a
full agonist (TIZ) in Cycle 1 and as a neutral antagonist
(T=Z) in Cycle 2. In contrast, Ligand 2 is de¢ned as a neutral
antagonist (T=Z) in Cycle 1 and as a full agonist (TIZ) in
Cycle 2. The simulation shows that Ligand 1 behaves as a full
agonist in the wild-type and as a neutral antagonist in the
mutant receptor whereas the opposite occurs for Ligand 2.
However, both ligands behave as full agonists in panel C,
giving exactly the same concentration^e¡ect curves. The max-
imum responses yielded by both ligands in panel C would
decrease if the a⁄nities for the receptor species from the
cycles where they act as neutral antagonists increase. This
change will render Ligand 1 and Ligand 2 partial agonists.
4.2. The correlation between basal response and agonist
potency
Other pharmacological outcomes can be assessed properly
by the double two-state model of agonism, for instance, the
increment in basal response after receptor mutation leading to
constitutively active mutant receptors. Fig. 2 shows the con-
centration^e¡ect for a ligand in a wild-type receptor
(a12 = 1036) with relatively low basal response (fR =1036)
and in two mutant receptors (a12 = 106) in which the basal
response increases (Mutant 1, fR*=1035 and Mutant 2,
Fig. 2. The increment in basal response after receptor mutation and
its e¡ect on concentration^e¡ect curves for wild-type (a12 = 1036,
X1 = 1036, X2 = 1035, solid line), mutant 1 (a12 = 106, X1 = 1036,
X2 = 1035, short dashed line) and mutant 2 (a12 = 106, X1 = 1036,
X2 = 1034, long dashed line) receptors. The equilibrium constants
for the ligand^receptor interactions have been considered to be the
same for both cycles (Ti =1039, Zi =1, with i=1,2). Eq. 6 has been
employed in the simulations.
Fig. 3. A: Partial agonism depends on the a⁄nity ratio of the li-
gand for the inactive and active receptors. Cycle 1: X1 = 1033,
T1 = 1039, Z1 = 1036 ; Cycle 2: X2 = 1033, T2 = 1039, Z2 = 1033.
Wild-type 1: a12 = 1036, solid line; Mutant 1; a12 = 106, dashed line.
B: Partial agonism depends on the value of the equilibrium con-
stants for inactive and active receptors in the absence of agonist.
Cycle 1: X1 = 1033, T1 = 1039, Z1 = 1036 ; Cycle 2: X2 = 1031,
T2 = 1039, Z2 = 1036. Wild-type 2: a12 = 1036, solid line; Mutant 2:
a12 = 106, dashed line.
Fig. 4. A: An inverse agonist can be converted into a full agonist
by changing the a⁄nity ratio for the inactive and active receptors.
Cycle 1: X1 = 1033, T1 = 1, Z1 = 1039 ; Cycle 2: X2 = 1033, T2 = 1039,
Z2 = 1. Wild-type 1: a12 = 1036, solid line; Mutant 1: a12 = 106,
dashed line. B: An inverse agonist remains as that although with
higher basal activity if the value of the constant for the equilibrium
between R and R* increases. Cycle 1: X1 = 1033, T1 = 1, Z1 = 1039 ;
Cycle 2: X2 = 1, T2 = 1, Z2 = 1039. Wild-type 2: a12 = 1036, solid
line; Mutant 2: a12 = 106, dashed line.
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fR*=1034). It can be seen that changing the value of the
equilibrium constant X between R and R* receptor conforma-
tions (X1 = 1036 rules for the wild-type and X2 = 1035 and
X2 = 1034 for the Mutant 1 and Mutant 2 receptors, respec-
tively) has a profound impact on the observed concentration^
e¡ect curves: the ligand, which has not changed its a⁄nity
constants for the di¡erent forms of the receptor, appears to be
more potent in either of the mutants than in the wild-type
receptor. Moreover, the increment in the potency of the ago-
nist is correlated with the shift of the equilibrium between R
and R* towards R* as measured by the constant X.
4.3. Partial agonists can be converted into full agonists
Within the two-state model [7], an agonist is a ligand which
presents more a⁄nity for the active than for the inactive re-
ceptor (T6Z). The ratio between these two constants deter-
mines that the agonist is full or partial. Fig. 3 shows two ways
in which a partial agonist is converted into a full agonist after
receptor mutation (a12 = 1036 for the wild-type and a12 = 106
for the mutant receptor). See Eq. 6. In panel A, the dissoci-
ation constant of the ligand for the inactive receptor is higher
in Cycle 2 than in Cycle 1 (Z2 = 1033sZ1 = 1036). In panel B,
the ligand displays the same values for the ligand^receptor
equilibrium constants in both cycles (Ti =1039 ; Zi =1036).
However, in Cycle 2 the basal response is augmented
(X2sX1).
4.4. Inverse agonists can be converted into full agonists
Fig. 4A shows the concentration^e¡ect curves of a ligand,
which is de¢ned as an inverse agonist for Cycle 1 and as a full
agonist for Cycle 2. Assuming that Cycle 1 is majority in the
wild-type receptor (a12 = 1036) and Cycle 2 is majority in the
mutant receptor (a12 = 106) allows the ligand to perform op-
posite roles. In Fig. 4B the ligand is intrinsically an inverse
agonist with identical ligand^receptor equilibrium constants
for both cycles (Ti =1; Zi =1039). However, in Cycle 2 the
constant for the equilibrium between R and R* increases
(X2 = 1sX1 = 1033). This change does not alter the de¢nition
of the ligand, which is still an inverse agonist. Yet, the basal
response is higher in the mutant than in the wild-type recep-
tor.
5. Concluding remarks
A number of simulations have been performed with the
double two-state model of agonism. This model assumes
that the functional response of a receptor is determined by
the sum of two interdependent cycles. Receptor mutation may
alter the value of the constant that measures the importance
of one cycle relative to the other, and this allows the pharma-
cological pro¢le of a system to be simulated before and after
mutation. The present model is closely related to the three-
state receptor model of agonist action [18,19], where one in-
active and two active conformations of the receptor were pro-
posed to exist. Although the latter model was used to simulate
multiple transduction pathways rather than the e¡ects of re-
ceptor mutation, the kinds of variation of ligand pharmacol-
ogy predicted by both models are coincident.
With respect to the main issue of the present paper, the
discussion between conformational selection and agonist in-
duction mechanisms, it can be seen that by substituting
Ti = (XiZi)/Yi with i=1 or 2 in Eq. 6, new relationships for
the agonist induction mechanism are obtained, which are
equivalent to those produced by the conformational selection
approach. It should be noted that the parameters in the fore-
going equations involve concentrations at equilibrium of the
ligand, the receptor and the ligand^receptor complexes. Be-
cause of the thermodynamic nature of the model, the confor-
mational pathways followed by the molecular entities between
the di¡erent steady states are ignored. Thus, it may be con-
cluded that it is not possible to distinguish between the above
mechanisms within a purely thermodynamic framework. This
result agrees with the previous statement [3] that there is no
dichotomy between the mechanisms of receptor selection and
agonist induction if the energy landscape idea with the pres-
ence of multiple active states is accepted. Nevertheless, new
insights into this intriguing point can be obtained from re-
search areas where kinetics and molecular mechanisms play
crucial roles. Thus, £uorescence studies can provide essential
details on the conformational changes undergone by the re-
ceptor upon agonist binding [20]. Although £uorescence life-
time spectroscopy experiments on the L2 adrenergic receptor
[21] are consistent with the agonist induction mechanism, fur-
ther investigations would be needed to reconcile these results
with the existence of basal activity. This property requires the
presence of a signi¢cant concentration of active native recep-
tors, which, in principle, could be a¡ected by the addition of
agonist molecules. Interestingly, the use of single-molecule
techniques revealed that the native L2 receptor exists in several
conformational substates in equilibrium and that the full ago-
nist isoproterenol seems to stabilize substates that might be
rare in the native receptor [22]. The authors hypothesized that
one or more of the states having the smaller probabilities
represent the active state of the receptor. These ¢ndings are
compatible with both selection and induction mechanisms.
From a di¡erent perspective, structure^activity studies can
also be helpful for testing hypotheses on receptor activation.
Thus, at the stage of rational design of agonists for a partic-
ular receptor system, one can devise ligand structures suitable
to bind preferably R* (conformational selection) or ligand
molecular structures suitable to bind preferably R, but con-
taining the chemical groups necessary for triggering the pro-
cess of receptor activation (agonist induction). As has been
shown [23], because the ligands and the residues from the
receptor active site are in chemical equilibrium between di¡er-
ent ionic and tautomeric forms, there is not a unique route for
receptor activation. In fact, the existence of two ligand con-
formations (A, A*) in equilibrium, one (A*) recognized by R*
and the other (A) recognized by R, is implicit in the two-state
model. Thus, it is possible that some agonists are more prone
to transmit the signal by binding R* whereas others proceed
mainly by binding R and inducing the conformational change
to R*. This approach implies the examination of the potential
mechanisms of signal transduction in relation to the molecular
structures of the ligands. Structure^activity studies focusing
on this topic can be useful both for providing a better under-
standing of the processes of receptor recognition and activa-
tion and for introducing more diversity in the generation of
ligand molecules.
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